Table 1 Clinical characteristics and cancer-specific survival in patients with inoperable gastro-oesophageal cancer: univariate survival analysis
Patients 258 (100%) | Survival (months) median (95% CI) | P -value | |
|---|---|---|---|
Age (years) | |||
<65 | 91 (35) | 8.0 (7.0–9.0) | |
65–74 | 64 (25) | 6.6 (2.5–10.8) | |
>75 | 103 (40) | 7.4 (4.8–10.1) | 0.664 |
Sex | |||
Male | 166 (64) | 7.4 (5.7–9.1) | |
Female | 92 (36) | 8.0 (6.2–9.9) | 0.728 |
Tumour type | |||
Adenocarcinoma | 187 (73) | 8.2 (6.2–9.6) | |
Squamous | 71 (27) | 6.6 (4.9–8.3) | 0.979 |
Tumour site | |||
Oesophagus | 142 (55) | 8.9 (6.8–11.1) | |
Gastric | 116 (45) | 6.6 (4.0–9.3) | 0.042 |
TNM stage | |||
I | 29 (11) | 20.5 (13.3–27.7) | |
II | 27 (11) | 11.8 (8.3–15.3) | |
III | 64 (25) | 9.8 (8.1–11.5) | |
IV | 138 (53) | 4.5 (2.4–6.5) | <0.001 |
Alkaline phosphatase (U l−1) | |||
Tertile 1 (n=85) | 145 (19–176)a | 8.4 (6.7–10.2) | |
Tertile 2 (n=85) | 199 (176–233) | 8.9 (6.8–11.1) | |
Tertile 3 (n=84) | 325 (235–2396) | 5.0 (2.1–7.9) | 0.050 |
GPS | |||
0 | 92 (36) | 13.6 (9.2–18.1) | |
1 | 121 (47) | 6.3 (4.2–8.5) | |
2 | 45 (17) | 2.4 (0.5–4.4) | <0.001 |
Treatment | |||
Active | 195 (76) | 10.1 (8.6–11.6) | |
Supportive | 63 (24) | 2.1 (1.3–2.8) | <0.001 |
